C alcific aortic valve disease (CAVD) is the most common indication for valve intervention in the world. 1 The cellular mechanisms, cardiovascular risk factors, and therapeutic interventions have been under intense investigation in the 21st century. In the study published in ATVB, Cao et al 2 tested the Multi-Ethnic Study of Atherosclerosis (MESA) database to define the calcification phenotype associated with unique lipoprotein mechanisms in the development of calcification. MESA was designed to test subclinical atherosclerosis markers and measure calcification burden in the aortic valve using computed tomography measurements. The study group included individuals from age 45 to 84 years, who were free of any clinical cardiovascular disease and treated diabetes mellitus. 3, 4 The database is robust to test for subclinical risk factors in the development of calcific aortic valve disease.
See accompanying article on page 1003

Lipoproteins as Novel Risk Factors in Calcific Aortic Valve Disease
O'Brien et al 5 and Otto et al 6 publish studies to define the role of lipoproteins in ex vivo calcified aortic valves. Over the next 20 years, studies in the field of calcific aortic valve disease have determined that the calcific aortic valve disease is not a degenerative process, but an active cellular biology. 1 This hypothesis was confirmed using animal models, which tested the role of hypercholesterolemia as an initiating event for calcific aortic valve disease. 7 In 2009, the National Heart, Lung, and Blood Institute convened a working group on the cellular mechanisms of calcific aortic valve disease. 1 The working hypothesis for the development of calcific aortic valve disease emphasized the role of lipoproteins and oxidative stress in the initiation of the disease. 8 Calcification ensues over time as aortic valve myofibroblasts differentiate into an osteogenic phenotype. [9] [10] [11] 
Role of MESA in CAVD
MESA has played an important role in studying the development of calcification in the aortic valve and coronary artery. [12] [13] [14] [15] In this study by Cao et al, 2 they define the cutoffs for Lp(a) and the effect of ethnicity in the development of CAVD. Lp(a) concentrations were measured using a turbidimetric immunoassay, and subclinical CAVD was measured by quantifying aortic valve calcification (AVC) through computed tomographic scanning in 4678 participants of the Multi-Ethnic Study of Atherosclerosis. Relative risk (RR) and ordered logistic regression analysis determined cross-sectional associations of Lp(a) with AVC and its severity, respectively. The conventional 30 mg/dL Lp(a) clinical cutoff was associated with AVC in white (RR, 1.56; 95% confidence interval, 1.24-1.96) and was borderline significant (P=0.059) in black study participants (RR, 1.55; 95% confidence interval, 0.98-2.44). Whites with levels ≥50 mg/dL also showed higher prevalence of AVC (RR, 1.72; 95% confidence interval, 1.36-2.17) than those below this level. Significant associations were observed between Lp(a) and degree of AVC in both white and black individuals. The degree of AVC in Asians and Hispanic is not significant, but this could be because of the results being underpowered in these populations tested.
Lipoprotein Analysis in Coronary Artery Calcification
The presence of existing coronary artery calcification did not affect these associations of Lp(a) and CAVD. There were no significant findings in Hispanics or Chinese. In contrast, CAC was only associated with AVC in the subcohort using a regression model and adjusting for age, sex, education, diabetes mellitus, systolic blood pressure, hypertension meds, smoking, low-density lipoprotein, high-density lipoprotein, and triglycerides (RR, 1.71; P<0.001). All of the traditional risk factors important in the development of CAVD. 1 Importantly, CAC was not associated with Lp(a) in this MESA data set, and the inclusion of CAC into statistical models did not appreciably influence relations of Lp(a) and AVC in the subcohort or among races/ethnicities.
Lp(a) in Calcific Aortic Valve Disease
In 2016, Cao et al, 2 discovery of Lp(a) in MESA as a risk factor for CAVD teases out the role of traditional risk factors versus Lp(a). The MESA data set, and the inclusion of CAC into statistical models, did not appreciably influence relations of Lp(a) and AVC in the subcohort or among races/ ethnicities. This finding differentiates the role of Lp(a) in the progression of AVC, which is not related to the presence of CAC in the population. This may be because of the mechanism of coronary artery calcification 16 versus AVC 9 versus the role of embryonic cell linage 17 in the mechanism of calcification. Previous investigations have also defined the importance of Lp(a) in the development of CAVD in genetic studies. 18 Thanassoulis 19 has further proposed that targeted therapy of Lp(a) may be a novel target for treating calcific aortic valve disease. The role of multiple lipoproteins in the progression of CAVD, may further aid in understanding the outcomes of the clinical trials in CAVD, [20] [21] [22] [23] designed to lower lipids in calcific aortic valve disease. ASTRONOMER specifically addressed this question by determining the role of oxidized phospholipids and Lp(a) in the progression of calcific aortic valve disease. 24 It is well known that traditional risk factors play a role in the majority of patients with CAVD 1 ; however, genetics 25 and lipoprotein Lp(a) 2 
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